RNAi inhibition of CTGF for treatment of ocular disorders
AssigneeAlcon Inc.
InventorsAllan R. Shepard, Iok-Hou Pang
Life of this patent
Estimating the term…
Abstract
RNA interference is provided for inhibition of connective tissue growth factor mRNA expression in ocular disorders involving CTGF expression. Ocular disorders involving aberrant CTGF expression include glaucoma, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and wound healing. Such disorders are treated by administering interfering RNAs of the present invention.
Claims10
A method of attenuating expression of connective tissue growth factor mRNA in an eye of a subject, said method comprising:
- administering by ocular injection to said eye of said subject a composition comprising an effective amount of an interfering RNA consisting of a length of 21 to 49 nucleotides and a pharmaceutically acceptable carrier, said interfering RNA comprising:
- 5′-gggcaaaaagugcauccguTT-3′ SEQ ID NO:
- 32 (sense nucleotide sequence) and 3′-TTcccguuuuucacguaggca-5′ SEQ ID NO:
- 33 (antisense nucleotide sequence), wherein the expression of connective tissue growth factor mRNA is attenuated.
A method of treating glaucoma in a subject in need thereof, said method comprising:
- administering by ocular injection to an eye of said subject a composition comprising an effective amount of an interfering RNA consisting of a length of 21 to 49 nucleotides and a pharmaceutically acceptable carrier, said interfering RNA comprising:
- 5′-gggcaaaaagugcauccguTT-3′ SEQ ID NO:
- 32 (sense nucleotide sequence) and 3′-TTcccguuuuucacguaggca-5′ SEQ ID NO:
- 33 (antisense nucleotide sequence), wherein said glaucoma is treated thereby.
Dependencies are inferred from the claim text.